EmailHospital Circular 35/2009
Date Issued: 22 December 2009
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 January 2010.
We have received recent advice from the Commonwealth Department of Health and Ageing regarding changes to the Highly Specialised Drugs Program, effective 1 January 2010.
ADDED ITEM
TENOFOVIR with EMTRICITABINE and EFAVIRENZ
| 9650X | Tablet containing tenofovir disoproxil fumarate 300mg with emtricitabine 200mg and efavirenz 600mg | 30 | $1,217.74 | Atripla | GI |
Treatment of HIV infection in patients with:
- CD4 cell counts of less than 500 per cubic millimetre; or
- viral load of greater than 10,000 copies per mL.
Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website.
AMENDED RESTRICTION
ABATACEPT and
INFLIXIMAB
Amended restrictions for treatment of adult patients with severe active rheumatoid arthritis (Initial 1)
AMENDED NAME OF ITEMS
TENOFOVIR DISOPROXIL FUMARATE now known as
TENOFOVIR
TENOFOVIR DISOPROXIL FUMARATE with EMTRICITABINE now known as
TENOFOVIR with EMTICITABINE
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Maree Guyatt
Acting Executive Director,
Wellbeing, Integrated Care and Ageing
